PETN-induced antioxidant properties in endothelial cells as a target for secondary prevention of endothelial dysfunction in pregnancy.
These studies will lay the basic scientific foundation for clinical studies demonstrating the protective effect of PETN in pregnant women at increased risk for fetal growth restriction (FGR). Thus, this project is a typical example of translational research.
According to current knowledge, increased release of endothelium-activating soluble VEGF receptor-1 (sFlt-1) and endoglin from the placenta occurs in preeclampsia due to impaired trophoblast differentiation in early pregnancy (Huppertz 2008, Roberts 2009). At the same time, the endothelium-protective placental growth factor PlGF is produced in a reduced manner. There is an imbalance of endothelium-protective and endothelium-activating factors in the maternal circulation, leading to generalized endothelial dysfunction with coagulation activation, increase in endothelial permeability, and blood pressure elevation (Asif Ahmed and Wenda Ramma 2011). In FGR, trophoblast invasion and subsequently adequate conversion of spiral arteries into nonresistant vessels is insufficient. Perfusion of the placenta is impaired. FGR also results in impaired vascular function with increased sFlt-1 and decreased PlGF in the maternal circulation (Taylor 2003). Women who develop PE or FGR during pregnancy are at increased risk for cardiovascular disease throughout life due to impaired endothelial function (Brown et al. 2013).
NO donors cause vascular dilatation and thus a reduction in blood pressure. Continuous therapy with nitrates such as GTN leads to a decrease in the effect, the so-called nitrate tolerance. Taking the NO donor pentaerytrityl tetranitrate (PETN) does not show nitrate intolerance, but long-lasting vasodilation (Daiber et al. 2008). Furthermore, PETN induces the expression of the antioxidant heme oxygenase-1 (HO-1) in endothelial cells (Pautz et al. 2009, Daiber et al. 2012). The mechanism of action of HO-1 is based on the degradation of heme to carbon monoxide (CO), iron, and biliverdin, which is degraded to bilirubin (Sikorski et al. 2004). In this process, CO additionally acts as a vasodilator and bilirubin as an antioxidant. (George et al. 2014). In animal models, it has been shown that PETN-induced expression of HO-1 resulted in a decrease in the formation of oxygen radicals and a reduction in blood pressure without the emergence of nitrate tolerance (Schuhmacher et al. 2010, Wenzel et al. 2007). PETN furthermore slows down the progression of atherosclerosis as a consequence of increased expression of HO-1 (Polte et al. 2000, Oppermann et al. 2009). Conversely, in the absence of HO-1, there is extensive endothelial dysfunction with coagulation activation, intravascular hemolysis, and endothelial death (Yachie et al. 1999).
In a clinical trial at the University Women's Hospital in Jena, Germany, treatment with PETN was shown to reduce the risk of FGR, perinatal death, preterm delivery, and premature placental abruption in high-risk patients. In addition, there was a significantly milder course of PE that occurred later in pregnancy and was less frequently associated with preterm delivery and severe FGR (Schleussner et al. 2014). The reason for the more favorable course of the disease, in addition to the vasodilatory one, is most likely explained by the endothelium-protective effect of PETN. This relationship will be investigated and further elucidated in vitro in the present work.
HUVEC monolayers are used as a cellular model to study endothelial dysfunction in cell culture. Intact monolayer function is indicated by constant density with constant electrical resistance in impedance measurement in the XCelligence® system, continuous staining for interendothelial adhesion molecules such as VE-cadherin in immunocytology, and activation of survival signals by VEGF. These functions are disrupted by the addition of endothelial activating agents. The dysfunction of the endothelial monolayer in cell culture is then manifested by the breakdown of the barrier in the XCelligence® system, immunocytologically in a discontinuous staining pattern of VE-cadherin, in the release of endothelial activators, such as sFlt-1 into the cell culture medium and activation of signal transduction pathways mediating increased proliferation and migration of endothelial cells. In this process, signaling in endothelial cells is mediated mainly via VEGF receptor 2, which is in complex with VE-cadherin at the cell membrane in the stable endothelial cell monolayer and activates survival pathways in cells via PI3K and AKT.
In dysfunctional monolayers, activation of VEGFR2 via PKC activates ERK1/2 and stimulates migration and proliferation (Cross 2003): activation of VEGFR-2 with phosphorylation of the receptor at PY99 then also leads to the release of sFlt-1 (Cudmore 2007). It has been shown that HO-1 induction in endothelial cells leads to decreased release of sFlt-1 (Cudmore 2007). In vivo, HO-1 expression is triggered by various effectors in endothelial cells. Subsequently, it exerts intracellular antiapoptotic, antiproliferative, and anti-inflammatory effects via the accumulation of heme and CO (Loboda, 2016).